INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is a rare variant of the aggressive extranodal non-Hodgkin lymphoma of the diffuse large B-cell type. It accounts for about 1% of all lymphomas, 4%-6% of all extranodal lymphomas and 3% of all central nervous system (CNS) tumors. [1] The risk of developing PCNSL is highly associated with having congenital or acquired immunodeficiencies such as human immunodeficiency virus (HIV) infection. The incidence is highest in patients aged >65 years, who represent the largest proportion of immunocompetent patients. [2] [3] [4] Few population studies about PCNSL have been published in Saudi Arabia; however, recent studies have shown a slight female predominance, and the mean age at diagnosis has been found to be 50.4 years (range: 20 to ≥60 years). [5, 6] 
METHODS
A committee comprising experts in hematology and medical oncology was established under the supervision of the Saudi Lymphoma Group and in collaboration with the Saudi Oncology Society. For collecting evidence, a literature search was carried out with relevant keywords using online database search engines such as PubMed/Medline, Web of Science and Scopus. In addition, an expert's opinion was considered when necessary. The levels of evidence used in developing this guideline were as follows: This easy-to-follow grading system is convenient for readers to understand and allows an accurate assessment of the guideline's applicability in individual patients.
PATHOLOGIC DIAGNOSIS

Magnetic resonance imaging (MRI) with contrast
should be performed in all suspected cases of PCNSL to define the site and extent of disease 1.2. Fluid-attenuated inversion recovery and T1-weighted sequences before and after contrast injection are the methods of choice for diagnosis 1.3. The diagnosis of PNCSL should be confirmed pathologically according to the WHO classification (EL-1) [1] 1.4. Stereotactic needle brain biopsy is the optimal method to obtain a histopathological diagnosis; therefore, surgical reduction of PCNSL is not recommended (EL-3) [8] 1.5. Steroids should be withheld for at least 7-10 days prior to biopsy to minimize its lymphocytotoxic effect on histological diagnosis (EL-3) [9, 10] 1.6. The immunohistochemical markers for lymphoma cell characterization should include pan-B-cell antigens (i.e., CD19, CD20, CD22 and CD79a), BCL6, MUM1/IRF4, BCL2 and CD10 (EL-1) [1, 11, 12] 1.7. Other histologies for CNS lymphomas include Burkitt's lymphoma, lymphoblastic, indolent lymphoma (marginal zone lymphoma and small lymphocytic lymphoma) and T-cell lymphoma. [13] 3. MANAGEMENT 3.1. The treatment of PCNSL is based on age and performance status [14, 15] 3.2. High-dose methotrexate (HDMTX) (≥3 g/m2) is the standard induction therapy to cross the blood-brain barrier and yield cytotoxic levels in the CSF. It should be delivered over 2-4 h (rapid infusion) through at least 4-6 injections at intervals of not >2-3 weeks (EL-1) [16] [17] [18] 3.3. HDMTX infusions require pre-and posthyperhydration, urine alkalinization, leucovorin rescue and MTX concentration monitoring 3.4. HDMTX in combination with temozolomide and rituximab improves the response rates compared with HDMTX alone 3.5. High-dose consolidation of cytarabine and etoposide following HDMTX-based polychemotherapy induction therapy is recommended (EL-2) [19] 3.6. Palliative whole-brain radiotherapy should be considered for patients deemed unsuitable to receive HDMTX owing to tolerability or relapse after treatment with HDMTX and CNS-penetrating chemotherapy or being unfit for further chemotherapy (EL-3). 
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